Reach for Health Study: Obesity-related Mechanisms and Mortality in Breast Cancer Survivors
2020年5月17日 更新者:Ruth E. Patterson、University of California, San Diego
Obesity-related Mechanisms and Mortality in Breast Cancer Survivors
This objective of this randomized controlled trial is to conduct a 2x2 test of a lifestyle intervention and metformin (a drug used to treat diabetes) to investigate how these treatments, alone or in combination, affect biomarkers associated with breast cancer survival.
The Reach for Health Study will enroll 340 overweight/obese, postmenopausal breast cancer survivors.
After completing the screening process and baseline measures, participants will be randomized in equal numbers to: (1) placebo, (2) metformin, (3) lifestyle intervention and placebo, or (4) lifestyle intervention and metformin.
The intervention was powered on the main effects and the planned analyses are to compare: Metformin to Placebo and a separate comparison of Lifestyle intervention to control.
The interventions will last for 6 months.
Concentrations of circulating biomarkers will be assessed at baseline and 6 months.
研究概览
地位
完全的
条件
研究类型
介入性
注册 (实际的)
333
阶段
- 不适用
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习地点
-
-
California
-
La Jolla、California、美国、92093
- Moores UCSD Cancer Center
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
- 孩子
- 成人
- 年长者
接受健康志愿者
不
有资格学习的性别
女性
描述
Inclusion Criteria:
- BMI at least 25.0 kg/m2
- Diagnosed with Stage I, II, or III breast cancer within past 5 years
- Treatment with total mastectomy or breast-sparing surgical removal of cancer with clear macroscopic margins, and axillary dissection, followed by adjuvant breast radiation
- Not scheduled for or currently undergoing chemotherapy
- Accessible geographically and by telephone
- Able to communicate dietary and physical activity data via telephone
- If taking statins, tamoxifen, or aromatase inhibitors; able and willing to remain on treatment for 6-month study period
- Post-menopausal at diagnosis
Exclusion Criteria:
- Preliminary bloodwork outside of specified ranges
- Evidence of renal insufficiency, liver disease, or congestive heart failure
- Currently taking corticosteroid pills or steroid hormone therapy (including vaginal estrogen creams)
- Recent initiation (< 3 months ago) of thiazides or β-blockers
- Taking insulin or other antidiabetic drug
- Other primary or recurrent invasive cancer in past 10 years
- Unable to commit to study requirements
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:预防
- 分配:随机化
- 介入模型:阶乘赋值
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
有源比较器:Metformin + lifestyle intervention
|
Week 1: 500 mg at dinner time Weeks 2-4: 1000 mg at dinner time Weeks 5+: 500 mg in morning; 1000 mg at dinner time
Telephone-based lifestyle intervention (dietary change and physical activity) for weight loss.
|
|
有源比较器:Placebo + lifestyle intervention
|
Telephone-based lifestyle intervention (dietary change and physical activity) for weight loss.
Week 1: 1 pill at dinner time Weeks 2-4: 2 pills at dinner time Weeks 5+: 1 pill in morning; 2 pills at dinner time
其他名称:
|
|
有源比较器:Metformin + standard dietary guidelines
|
Week 1: 500 mg at dinner time Weeks 2-4: 1000 mg at dinner time Weeks 5+: 500 mg in morning; 1000 mg at dinner time
Set of standard health education materials provided to participants at single time point (immediately after randomization)
|
|
安慰剂比较:Placebo + standard dietary guidelines
|
Week 1: 1 pill at dinner time Weeks 2-4: 2 pills at dinner time Weeks 5+: 1 pill in morning; 2 pills at dinner time
其他名称:
Set of standard health education materials provided to participants at single time point (immediately after randomization)
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Insulin
大体时间:change from baseline to 6 months
|
Insulin measured as percent change from baseline
|
change from baseline to 6 months
|
|
Glucose
大体时间:change from baseline to 6 months
|
Glucose measured as percent change from baseline
|
change from baseline to 6 months
|
|
C-reactive Protein
大体时间:change from baseline to 6 months
|
C-reactive protein measured as percent change from baseline
|
change from baseline to 6 months
|
|
Bioavailable Testosterone
大体时间:change from baseline to 6 months
|
Bioavailable testosterone measured as percent change from baseline
|
change from baseline to 6 months
|
|
Serum Hormone Binding Globulin
大体时间:change from baseline to 6 months
|
Serum hormone binding globulin measured as percent change from baseline
|
change from baseline to 6 months
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
出版物和有用的链接
负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始
2011年8月1日
初级完成 (实际的)
2015年12月1日
研究完成 (实际的)
2016年12月1日
研究注册日期
首次提交
2011年2月23日
首先提交符合 QC 标准的
2011年2月23日
首次发布 (估计)
2011年2月24日
研究记录更新
最后更新发布 (实际的)
2020年6月5日
上次提交的符合 QC 标准的更新
2020年5月17日
最后验证
2020年5月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.